Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short term Debt (2020 - 2021)

Historic Short term Debt for BridgeBio Pharma (BBIO) over the last 2 years, with Q1 2021 value amounting to $3.6 million.

  • BridgeBio Pharma's Short term Debt changed N/A to $3.6 million in Q1 2021 from the same period last year, while for Mar 2021 it was $3.6 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2020, which is N/A changed from last year.
  • BridgeBio Pharma's Short term Debt amounted to $3.6 million in Q1 2021.
  • In the past 5 years, BridgeBio Pharma's Short term Debt ranged from a high of $3.6 million in Q1 2021 and a low of $1.5 million during Q4 2020